73
Participants
Start Date
August 7, 2018
Primary Completion Date
August 3, 2022
Study Completion Date
August 3, 2022
ATG-008
Approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg/QD and another 20 subjects will receive oral ATG-008 at an initial dose of 20mg/BID for 28 days each cycle.
Oncology Hospital of Haerbin Medical University, Harbin
China People PLA 81 Hospital, Nanjing
West China Hospital Sichuan University, Chengdu
Yunnan Cancer Hospital, Kunming
The first Hospital of Jilin University, Changchun
Hunan Province Oncology Hospital, Changsha
Daping Hospital, Chongqing
The first hospital of Chongqing medical university, Chongqing
Xiehe Hospital of Fujian Medical University, Fuzhou
Nanfang Hospital of Nanfang Medical University, Guangzhou
The first affiliated Hospital of Zhejiang University, Hangzhou
Zhejiang Province Oncology Hospital, Hangzhou
The first affiliated hospital of Anhui medical university, Hefei
The second affiliated hospital of Anhui medical university, Hefei
The first affiliated hospital of Guangxi Medical University, Nanning
Oncology Hospital of Fudan University, Shanghai
Zhongshan Hospital of Fudan University, Shanghai
General Hospital of the Northern War Zone of the Chinese People's Liberation Army, Shenyang
Tangdu Hospital of China PLA fourth medical university, Xi'an
Dong-A University Hospital, Busan
Pusan National Univ. Hospital, Busan
Kyungpook National Univ. Hospital, Daegu
Asan Medical Center, Seoul
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
China Medical University Hospital, Taichung
National Taiwan University Hospital, Taipei
Taipei Medical University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
Chang Gung Memorial Hospital-Linkuo, Taoyuan District
Lead Sponsor
Antengene Therapeutics Limited
INDUSTRY